Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
Jessica A PollardErin M GuestTodd A AlonzoRobert B GerbingMichael R LokenLisa Eidenschink BrodersenE Anders KolbRichard AplencSoheil MeshinchiSusana C RaimondiBetsy HirschAlan S GamisPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
GO added to conventional chemotherapy improved outcomes for KMT2A-r AML; consolidation with HSCT may further enhance outcomes. Future clinical trials should study CD33-targeted agents in combination with HSCT for pediatric KMT2A-r AML.
Keyphrases
- phase iii
- free survival
- clinical trial
- acute myeloid leukemia
- open label
- phase ii
- allogeneic hematopoietic stem cell transplantation
- double blind
- acute lymphoblastic leukemia
- young adults
- placebo controlled
- palliative care
- hematopoietic stem cell
- study protocol
- cancer therapy
- childhood cancer
- rectal cancer
- metabolic syndrome
- current status
- nk cells
- chemotherapy induced